MIST Share Price Performance
US$1.92
0.81 (72.97%)
76.0% undervalued intrinsic discount
US$8.00
Fair Value
Price US$1.92
AnalystHighTarget US$8.00
AnalystLowTarget US$2.00
AnalystConsensusTarget US$6.60
Fair ValueUS$8.00
Share Pricen/a
Milestone Pharmaceuticals Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
MIST Community Narratives
AN
Fair Value
·Fair Value US$8 76.4% undervalued intrinsic discount
FDA Approval And Shift To Self Administered Care Will Reshape This Cardiovascular Opportunity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$2 5.5% undervalued intrinsic discount
Payer Constraints On Self Administered PSVT Care Will Challenge Near Term Progress Yet Offer Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$6.6 71.4% undervalued intrinsic discount
Acute Cardiovascular Self Administration Will Reshape Treatment Patterns And Support Long Term Thesis
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
FDA Approval And Shift To Self Administered Care Will Reshape This Cardiovascular Opportunity
Catalysts About Milestone Pharmaceuticals Milestone Pharmaceuticals is a cardiovascular focused company centered on CARDAMYST, an etripamil nasal spray for on demand treatment of paroxysmal supraventricular tachycardia in adults. What are the underlying business or industry changes driving this perspective?Read more
AN
US$8
76.4% undervalued intrinsic discount
Fair Value
Profit Margin
23.36%
Future PE
1.74x
Price in 2029
US$9.74
Payer Constraints On Self Administered PSVT Care Will Challenge Near Term Progress Yet Offer Upside
Catalysts About Milestone Pharmaceuticals Milestone Pharmaceuticals is a cardiovascular-focused biopharmaceutical company with an FDA approved, self-administered intranasal therapy, CARDAMYST, for acute treatment of paroxysmal supraventricular tachycardia in adults. What are the underlying business or industry changes driving this perspective?Read more
AN
US$2
5.5% undervalued intrinsic discount
Fair Value
Profit Margin
19.89%
Future PE
1.45x
Price in 2029
US$2.44
Acute Cardiovascular Self Administration Will Reshape Treatment Patterns And Support Long Term Thesis
Catalysts About Milestone Pharmaceuticals Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for acute cardiovascular conditions, including paroxysmal supraventricular tachycardia through its intranasal etripamil product, CARDAMYST. What are the underlying business or industry changes driving this perspective?Read more
AN
US$6.6
71.4% undervalued intrinsic discount
Fair Value
Profit Margin
20.06%
Future PE
34.82x
Price in 2029
US$8.04
Trending Discussion
Recently Updated Narratives
AN
FDA Approval And Shift To Self Administered Care Will Reshape This Cardiovascular Opportunity
Fair Value: US$8 76.4% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Payer Constraints On Self Administered PSVT Care Will Challenge Near Term Progress Yet Offer Upside
Fair Value: US$2 5.5% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Acute Cardiovascular Self Administration Will Reshape Treatment Patterns And Support Long Term Thesis
Fair Value: US$6.6 71.4% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Milestone Pharmaceuticals Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 13, 2026
- -0.51
- 100.00%
- -4,078.78%
- 136.9%
About MIST
- Founded
- 2003
- Employees
- 38
- CEO
- WebsiteView website
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
